Chembond Material Technologies reported a 43.4% increase in consolidated net profit to ₹572.62 lakh for the quarter ended June 30, 2026, compared to ₹399.02 lakh in the corresponding period of the previous year. Revenue from operations rose 25.5% to ₹7,241.56 lakh from ₹5,767.50 lakh in the same quarter last year, driven by strong performance across its Specialty Chemicals and Animal Health segments. The Board of Directors approved the unaudited standalone and consolidated financial results at its meeting held on July 17, 2026.

The Specialty Chemicals segment contributed ₹6,205.48 lakh to the net turnover, while the Animal Health segment added ₹1,036.08 lakh. Total expenses for the quarter stood at ₹7,035.12 lakh, up from ₹5,496.12 lakh in the year-ago period. Profit before tax for the quarter was ₹582.99 lakh, compared to ₹536.53 lakh in Q1FY26. The company’s basic earnings per share (EPS) improved to ₹4.26 from ₹2.97 in the previous year.

On a standalone basis, the company reported a net profit of ₹450.33 lakh for Q1FY27, up from ₹316.95 lakh in the corresponding quarter of the previous year. Revenue from operations increased to ₹6,296.89 lakh from ₹4,892.03 lakh. Profit before tax remained largely flat at ₹455.16 lakh compared to ₹457.28 lakh in the prior year. Standalone basic EPS for the quarter was recorded at ₹3.35.

The financial results were subjected to a limited review by the Statutory Auditors. The auditors noted that the comparative figures for the corresponding quarter ended June 30, 2025, were reviewed by the predecessor auditor. The group’s operations include the manufacture of Specialty Chemicals, Vitamins & Minerals, Probiotic and Prebiotic Enzymes, and Feed Additives.

Consolidated Financial Results (Q1FY27)

Standalone Financial Results (Q1FY27)

Chembond Material Technologies Limited has approved the grant of 50,738 stock options to eligible employees under its Employee Stock Option Plan 2025. The Nomination and Remuneration Committee (NRC) sanctioned the issuance on July 17, 2026, providing an opportunity for staff to acquire equity stake in the company and its subsidiary. The options carry an exercise price of ₹171 per share, which is the cost employees will pay to convert the options into equity shares in the future.

The scheme, titled CHEMBOND – ESOP 2025, is compliant with the Securities and Exchange Board of India (SEBI) (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. Each stock option granted is convertible into one fully paid-up equity share with a face value of ₹5. The vesting schedule is structured over a maximum period of five years from the grant date, with a mandatory minimum gap of one year between the grant date and the vesting of these options.

Key Details of the Grant

The following table outlines the specific parameters of the stock options granted by the company:

The company confirmed that the options are currently not vested, exercised, or lapsed, as the process is at the initial grant stage. Consequently, details regarding money realized by exercise, total shares arising from exercise, and diluted earnings per share are not applicable at this time. The terms of the options are defined in the respective scheme documents, and no subsequent changes or cancellations have occurred yet.

This disclosure was submitted to the stock exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Suchita Singh, Company Secretary & Compliance Officer, signed the filing on behalf of Chembond Material Technologies Limited .